Darzalex Solid Tumor And PD-(L)1 Combo Future Dashed
Hopes for Genmab/Janssen's myeloma drug daratumumab in solid tumors have faded after the CALLISTO trial in combination with Roche's Tecentriq in NSCLC was halted for lack of benefit and increased mortality. The future is dim for Darzalex in combination with PD-(L)1 therapies in general.
You may also be interested in...
Genmab is planning for its post-Darzalex future by exploring bispecific immunotherapies in a collaboration with Immatics that should see it develop immunotherapies directed against three proprietary targets, with the option of two more.
Following failure of Incyte/Merck's epacadostat/Keytruda study, NewLink Genetics says it is reviewing its IDO clinical programs.
Development of the leading immune-oncology agent has hit the buffers for multiple myeloma but failure in this relatively small market should not materially impact the product's prospects.